<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f9b9e637-d236-4bc0-afca-bbbf1b1747ab"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use SEVELAMER HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SEVELAMER HYDROCHLORIDE TABLETS<br/>
      <br/>SEVELAMER HYDROCHLORIDE tablets, for oral use<br/>
      <br/>Initial U.S. Approval: 2000</title>
   <effectiveTime value="20250205"/>
   <setId root="ddecb552-5882-4e44-8fa7-37c9234dd1b9"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="156861945" root="1.3.6.1.4.1.519.1"/>
            <name>Zydus Pharmaceuticals USA Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="130443810" root="1.3.6.1.4.1.519.1"/>
                  <name>Navinta LLC</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="26772ba2-c10d-4c68-8a61-92d1bc48d7c9"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250205"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70710-2058" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sevelamer Hydrochloride<suffix/>
                        </name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Sevelamer Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="800" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="GLS2PGI8QG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SEVELAMER HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="941N5DUU5C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SEVELAMER</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5Z17386USF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIACETYLATED MONOGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VG6UJI79NF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE 200 LM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="180" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70710-2058-8" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250301"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA218966" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NAV;110</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="67363cb3-258d-4d28-b5c6-192c3f294720"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of sevelamer hydrochloride tablets in CKD patients who are not on dialysis have not been studied.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID92" styleCode="Disc">
                           <item>Sevelamer hydrochloride tablets are a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. (<linkHtml href="#ID1">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID3">
               <id root="4d360848-3a0c-4164-b6da-b7d6e9050619"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID4">
                     <content styleCode="italics">Patients Not Taking a Phosphate Binder</content>. The recommended starting dose of sevelamer hydrochloride tablets is 800 mg to 1600 mg orally, which can be administered as one or two 800 mg sevelamer hydrochloride tablets with meals based on serum phosphorus level. Table 1 provides recommended starting doses of sevelamer hydrochloride tablets for patients not taking a phosphate binder.</paragraph>
                  <table ID="ID5" width="614" styleCode="Noautorules">
                     <caption>  Table 1: Starting Dose for Dialysis Patients Not Taking a Phosphate Binder </caption>
                     <col width="294"/>
                     <col width="320"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Serum Phosphorus</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Sevelamer Hydrochloride Tablets 800 mg</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> &gt;5.5 and &lt;7.5 mg/dL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 tablet three times daily with meals<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> ≥7.5 and &lt;9.0 mg/dL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 tablets three times daily with meals<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> ≥9.0 mg/dL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 tablets three times daily with meals<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID6">
                     <content styleCode="italics">Patients Switching from Calcium Acetate</content>. In a study in 84 CKD patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride tablets and calcium acetate. Table 2 gives recommended starting doses of sevelamer hydrochloride tablets based on a patient's current calcium acetate dose.</paragraph>
                  <table ID="ID7" width="614" styleCode="Noautorules">
                     <caption>  Table 2: Starting Dose for Dialysis Patients Switching from Calcium Acetate to Sevelamer Hydrochloride Tablets </caption>
                     <col width="305"/>
                     <col width="309"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Calcium Acetate 667 mg</content>
                              <br/>
                              <content styleCode="bold"> (Tablets per meal)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Sevelamer Hydrochloride Tablets 800 mg</content>
                              <br/>
                              <content styleCode="bold"> (Tablets per meal)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 1 tablet<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 tablet <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 2 tablets<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 tablets<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 3 tablets <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 tablets <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID8">
                     <content styleCode="italics">Dose Titration for All Patients Taking Sevelamer Hydrochloride Tablets</content>. Adjust dosage based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dL or less. Increase or decrease by one tablet per meal at two-week intervals as necessary. Table 3 gives a dose titration guideline. The average dose in a Phase 3 trial designed to lower serum phosphorus to 5.0 mg/dL or less was approximately three sevelamer hydrochloride 800 mg tablets per meal. The maximum average daily sevelamer hydrochloride tablets dose studied was 13 g.</paragraph>
                  <table ID="ID9" width="673" styleCode="Noautorules">
                     <caption>  Table 3: Dose Titration Guideline </caption>
                     <col width="330"/>
                     <col width="343"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Serum Phosphorus</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Sevelamer Hydrochloride Tablets Dose</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> &gt;5.5 mg/dL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> Increase 1 tablet per meal at 2-week intervals<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 3.5-5.5 mg/dL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> Maintain current dose<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> &lt;3.5 mg/dL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center"> Decrease 1 tablet per meal<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID93" styleCode="Disc">
                           <item>Starting dose is one or two 800 mg tablets orally three times per day with meals. (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Adjust by one tablet per meal in two-week intervals as needed to obtain serum phosphorus target (3.5 to 5.5 mg/dL). (<linkHtml href="#ID3">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID10">
               <id root="b8e0ac31-fe44-4871-b0e5-094691d000b8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID11">800 mg Tablets: White to off-white, oval shaped film coated tablet, debossed with "NAV" on one side and debossed with "110" on other side.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID94" styleCode="Disc">
                           <item>Tablets: 800 mg (<linkHtml href="#ID10">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID12">
               <id root="287d8526-4c4a-4ebf-9c68-22e375d2a45d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID13">Sevelamer hydrochloride tablets are contraindicated in patients with bowel obstruction.</paragraph>
                  <paragraph>Sevelamer hydrochloride tablets are contraindicated in patients with known hypersensitivity to sevelamer hydrochloride or to any of the excipients.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID95" styleCode="Disc">
                           <item>Bowel obstruction. (<linkHtml href="#ID12">4</linkHtml>)</item>
                           <item>Known hypersensitivity to sevelamer hydrochloride or to any of the excipients. (<linkHtml href="#ID12">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID14">
               <id root="9a01a8ec-ba3a-44df-9669-525c7eac7c63"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID96" styleCode="Disc">
                           <item>Serious cases of dysphagia, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. (<linkHtml href="#ID15">5.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID15">
                     <id root="b0532e60-a164-4d84-8e9f-722c7023d44d"/>
                     <title>5.1 Gastrointestinal Adverse Events</title>
                     <text>
                        <paragraph ID="ID16">Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders, including severe constipation, or major GI tract surgery were not included in the sevelamer hydrochloride clinical studies.</paragraph>
                        <paragraph>Dysphagia and esophageal tablet retention have been reported in association with use of sevelamer tablets, some requiring hospitalization and intervention. Consider using sevelamer suspension in patients with a history of swallowing disorders.</paragraph>
                        <paragraph>Cases of bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have also been reported with sevelamer use <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID24">6.2</linkHtml>)]</content>. Inflammatory disorders may resolve upon sevelamer hydrochloride discontinuation. Treatment with sevelamer hydrochloride should be re-evaluated in patients who develop severe gastrointestinal symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID17">
                     <id root="a85d48a2-0e19-44a4-bae3-b24f2b8339ac"/>
                     <title>5.2 Monitor Serum Chemistries</title>
                     <text>
                        <paragraph ID="ID18">Bicarbonate and chloride levels should be monitored.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID19">
                     <id root="8d98ba04-06ba-43fe-90a5-69bf96aa59f6"/>
                     <title>5.3 Monitor for Reduced Vitamins D, E, K (clotting factors) and Folic Acid Levels</title>
                     <text>
                        <paragraph ID="ID20">In preclinical studies in rats and dogs, sevelamer hydrochloride reduced vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of 6 to 10 times the recommended human dose. In short-term clinical trials, there was no evidence of reduction in serum levels of vitamins. However, in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55 ng/mL) fell from 39 ± 22 ng/mL to 34 ± 22 ng/mL (p&lt;0.01) with sevelamer hydrochloride treatment. Most (approximately 75%) patients in sevelamer hydrochloride clinical trials received vitamin supplements, which is typical of patients on dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID21">
               <id root="25e55e6e-b38b-4ab7-bbc0-2a0f66132767"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID97" styleCode="Disc">
                           <item>The most common reasons for discontinuing treatment were gastrointestinal adverse reactions. (<linkHtml href="#ID22">6.1</linkHtml>)</item>
                           <item>In a parallel design study of 12 weeks duration, treatment-emergent adverse reactions to Sevelamer hydrochloride tablets in peritoneal dialysis patients included dyspepsia (12%), peritonitis (8%), diarrhea (5%), nausea (5%), constipation (4%), pruritus (4%), abdominal distension (3%), vomiting (3%), fatigue (3%), anorexia (3%), and arthralgia (3%). (<linkHtml href="#ID22">6.1</linkHtml>)</item>
                           <item>Cases of fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation have been reported. (<linkHtml href="#ID24">6.2</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID98">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID22">
                     <id root="9f33fbd0-da4a-4006-8f4c-81e28b12cdbf"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID23">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In a parallel design study of sevelamer hydrochloride with treatment duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride (n=99) were similar to those reported for the active-control group (n=101). Overall adverse reactions among those treated with sevelamer hydrochloride occurring in &gt;5% of patients included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%), and constipation (8%). A total of 27 patients treated with sevelamer and 10 patients treated with comparator withdrew from the study due to adverse reactions.</paragraph>
                        <paragraph>Based on studies of 8 to 52 weeks, the most common reason for withdrawal from sevelamer hydrochloride was gastrointestinal adverse reactions (3%-16%).</paragraph>
                        <paragraph>In 143 peritoneal dialysis patients studied for 12 weeks, most adverse reactions were similar to adverse reactions observed in hemodialysis patients. The most frequently occurring treatment- emergent serious adverse reaction was peritonitis (8 reactions in 8 patients [8%] in the sevelamer group and 2 reactions in 2 patients [4%] on active control). Thirteen patients (14%) in the sevelamer group and 9 patients (20%) in the active-control group discontinued, mostly for gastrointestinal adverse reactions. Patients on peritoneal dialysis should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID24">
                     <id root="e267bb68-3ba2-402a-ba76-b0310295d9c2"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID25">The following adverse reactions have been identified during postapproval use of sevelamer hydrochloride tablets: hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction and uncommon cases of ileus, intestinal obstruction, and intestinal perforation. Appropriate medical management should be given to patients who develop constipation or have worsening of existing constipation to avoid severe complications.</paragraph>
                        <paragraph>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID26">
               <id root="4bf5fe4a-0c66-4df4-931e-62be2b9ac631"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID27">There are no empirical data on avoiding drug interactions between sevelamer hydrochloride and most concomitant oral drugs. For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#ID49">12.3</linkHtml>)</content>]. The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate-release or an extended-release product. Where possible monitor clinical responses or blood levels of concomitant drugs that have a narrow therapeutic range.</paragraph>
                  <table ID="ID28" width="622" styleCode="Noautorules">
                     <caption>  Table 4: Sevelamer Drug Interactions </caption>
                     <col width="284"/>
                     <col width="338"/>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Oral drugs for which sevelamer did not alter the pharmacokinetics when administered</content>
                              <br/>
                              <content styleCode="bold"> concomitantly</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Botrule Rrule" align="left"> Digoxin<br/> Enalapril<br/> Iron<br/> Metoprolol<br/> Warfarin<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride </content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Ciprofloxacin<br/> Mycophenolate mofetil<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left">
                              <content styleCode="bold"> Dosing Recommendations</content>
                              <br/> Take at least 2 hours before or 6 hours after sevelamer<br/> Take at least 2 hours before sevelamer<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID99" styleCode="Disc">
                           <item>When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concomitant medication. (<linkHtml href="#ID26">7</linkHtml>)</item>
                           <item>Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol, and warfarin. (<linkHtml href="#ID26">7</linkHtml>)</item>
                           <item>Sevelamer binds ciprofloxacin and mycophenolate mofetil; dose these drugs separately from sevelamer hydrochloride. (<linkHtml href="#ID26">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID29">
               <id root="d21165c8-347e-4376-89fa-1d5e2cb9b69a"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250205"/>
               <component>
                  <section ID="ID30">
                     <id root="cab51b66-fcbb-466c-89c9-a8fed8dd618d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID31">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Sevelamer hydrochloride is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Sevelamer hydrochloride may decrease serum levels of fat-soluble vitamins and folic acid in pregnant women <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID47">12.2</linkHtml>)]</content>. Consider supplementing with these vitamins.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Animal data</paragraph>
                        <paragraph>In pregnant rats given dietary doses of 0.5, 1.5, or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin D, occurred at 7-21 times the maximum human equivalent dose of 13 g based on 60 kg body weight. In pregnant rabbits given oral doses of 100, 500, or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose approximately 5 times the maximum clinical trial dose based on 60 kg body weight).</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID32">
                     <id root="64145249-ce14-4779-bd6c-3eeb39d5686b"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID33">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Sevelamer hydrochloride is not absorbed systemically by the mother following oral administration and breastfeeding is not expected to result in exposure of the child to sevelamer hydrochloride.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Sevelamer hydrochloride may decrease serum levels of fat-soluble vitamins and folic acid in lactating women <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID47">12.2</linkHtml>)].</content> Consider supplementing with these vitamins.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID34">
                     <id root="c564381f-77c5-4934-99b0-59a5803a214a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID35">The safety and efficacy of sevelamer hydrochloride has not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID36">
                     <id root="d5cff091-f3a2-45dd-8aad-82cbabb6ab2e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID37">Clinical studies of sevelamer hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID38">
               <id root="a77c3b0d-b159-4b63-946b-46df64ebc530"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID39">Sevelamer hydrochloride has been given to normal healthy volunteers in doses of up to 14 g per day for eight days with no adverse effects. Sevelamer hydrochloride has been given in average doses up to 13 g per day to hemodialysis patients. There are no reports of overdosage with sevelamer hydrochloride in patients. Since sevelamer hydrochloride is not absorbed, the risk of systemic toxicity is low.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
            </section>
         </component>
         <component>
            <section ID="ID40">
               <id root="603a9426-f2ba-4c9d-b288-f9277f666798"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID41">The active ingredient in sevelamer hydrochloride tablets is sevelamer hydrochloride, a polymeric amine that binds phosphate and is meant for oral administration. Sevelamer hydrochloride is poly(allylamine hydrochloride) crosslinked with epichlorohydrin in which 40% of the amines are protonated. It is known chemically as poly(allylamine-<content styleCode="underline">co</content>-N,N′-diallyl-1,3-diamino-2-hydroxypropane) hydrochloride. Sevelamer hydrochloride is hydrophilic, but insoluble in water.</paragraph>
                  <paragraph>The structure is represented in Figure 1.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Chemical Structure of Sevelamer Hydrochloride</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID43">The primary amine groups shown in the structure are derived directly from poly(allylamine hydrochloride). The crosslinking groups consist of two secondary amine groups derived from poly(allylamine hydrochloride) and one molecule of epichlorohydrin.</paragraph>
                  <paragraph>Sevelamer Hydrochloride Tablets: Each film-coated tablet of sevelamer hydrochloride contains 800 mg of sevelamer hydrochloride on an anhydrous basis. The inactive ingredients are microcrystalline cellulose, silicon dioxide, sodium stearyl fumarate and purified water. The film coating contains di-acetylated monoglycerides, hypromellose, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Figure 1: Chemical Structure of Sevelamer Hydrochloride</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f9b9e637-d236-4bc0-afca-bbbf1b1747ab-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID44">
               <id root="089d9e72-fe73-4e3e-a43c-2d95f774bd61"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250205"/>
               <component>
                  <section ID="ID45">
                     <id root="e5dad222-7877-4f9c-a149-13867e2802ab"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID46">Sevelamer hydrochloride tablets contain sevelamer hydrochloride, a non-absorbed binding crosslinked polymer. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the dietary tract and decreasing absorption, sevelamer hydrochloride lowers the phosphate concentration in the serum.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID47">
                     <id root="387b881d-da48-42ea-9d7f-7d4e9dc42881"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID48">In addition to effects on serum phosphate levels, sevelamer hydrochloride has been shown to bind bile acids <content styleCode="italics">in vitro </content>and <content styleCode="italics">in vivo </content>in experimental animal models. Bile acid binding by ion exchange resins is a well-established method of lowering blood cholesterol. Because sevelamer binds bile acids, it may interfere with normal fat absorption and thus may reduce absorption of fat-soluble vitamins such as A, D, and K. In clinical trials of sevelamer hydrochloride, both the mean total and LDL cholesterol declined by 15% to 31%. This effect is observed after 2 weeks. Triglycerides, HDL cholesterol, and albumin did not change.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID49">
                     <id root="3e3228bc-700a-4abc-91f9-af70a70319c7"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID50">A mass balance study using <sup>14</sup>C-sevelamer hydrochloride, in 16 healthy male and female volunteers showed that sevelamer hydrochloride is not systemically absorbed. No absorption studies have been performed in patients with renal disease.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>In vivo</paragraph>
                        <paragraph>Sevelamer carbonate has been studied in human drug-drug interaction studies (9.6 g once daily with a meal) with warfarin and digoxin. Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been studied in human drug-drug interaction studies (2.4-2.8 g single dose or three times daily with meals or two times daily without meals) with ciprofloxacin, digoxin, enalapril, iron, metoprolol, mycophenolate mofetil and warfarin.</paragraph>
                        <paragraph>Coadministered single dose of 2.8 g of sevelamer hydrochloride in fasted state decreased the bioavailability of ciprofloxacin by approximately 50% in healthy subjects.</paragraph>
                        <paragraph>Concomitant administration of sevelamer and mycophenolate mofetil in adult and pediatric patients decreased the mean MPA C<sub>max</sub> and AUC<sub>0-12h</sub> by 36% and 26%, respectively.</paragraph>
                        <paragraph>Sevelamer carbonate or sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of enalapril, digoxin, iron, metoprolol and warfarin when coadministered.</paragraph>
                        <paragraph>During postmarketing experience, cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients coadministered sevelamer hydrochloride and levothyroxine. Reduction in concentrations of cyclosporine and tacrolimus leading to dose increases has also been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (e.g., graft rejection). The possibility of an interaction cannot be excluded with these drugs.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID51">
               <id root="edd46ea6-9bc5-4ca8-a1e5-5d4dc7a99387"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250205"/>
               <component>
                  <section ID="ID52">
                     <id root="04aa0d00-cdb3-4090-a83c-a282e196d2df"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID53">Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 g/kg/day. There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high-dose group (human equivalent dose twice the maximum clinical trial dose of 13 g). Mice received dietary administration of sevelamer hydrochloride at doses of up to 9 g/kg/day (human equivalent dose 3 times the maximum clinical trial dose). There was no increased incidence of tumors observed in mice. </paragraph>
                        <paragraph>In an <content styleCode="italics">in vitro </content>mammalian cytogenetic test with metabolic activation, sevelamer hydrochloride caused a statistically significant increase in the number of structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in the Ames bacterial mutation assay. </paragraph>
                        <paragraph>Sevelamer hydrochloride did not impair the fertility of male or female rats in a dietary administration study in which the females were treated from 14 days prior to mating through gestation and the males were treated for 28 days prior to mating. The highest dose in this study was 4.5 g/kg/day (human equivalent dose 3 times the maximum clinical trial dose of 13 g).</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID54">
               <id root="e6fbfd27-4a38-49bb-bf2b-c9742cc8f11c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID55">The ability of sevelamer hydrochloride to lower serum phosphorus in CKD patients on dialysis was demonstrated in six clinical trials: one double-blind placebo-controlled 2-week study (sevelamer hydrochloride N=24); two open-label uncontrolled 8-week studies (sevelamer hydrochloride N=220) and three active-controlled open-label studies with treatment durations of 8 to 52 weeks (sevelamer hydrochloride N=256). Three of the active-controlled studies are described here. One is a crossover study with two 8-week periods comparing sevelamer hydrochloride to an active-control. The second is a 52-week parallel study comparing sevelamer hydrochloride with active control. The third is a 12-week parallel study comparing sevelamer hydrochloride and active control in peritoneal dialysis patients.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
               <component>
                  <section ID="ID56">
                     <id root="c12daa54-919c-4821-bbcb-96cf4469e436"/>
                     <title>14.1 Active-Control, Cross-Over Study in Hemodialysis Patients</title>
                     <text>
                        <paragraph ID="ID57">Eighty-four CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus &gt;6.0 mg/dL) following a two-week phosphate-binder washout period received sevelamer hydrochloride and active control for eight weeks each in random order. Treatment periods were separated by a two-week phosphate-binder washout period. Patients started on treatment three times per day with meals. Over each eight-week treatment period, at three separate time points the dose of sevelamer hydrochloride could be titrated up 1 capsule or tablet per meal (3 per day) to control serum phosphorus, the dose of active control could also be altered to attain phosphate control. Both treatments significantly decreased mean serum phosphorus by about 2 mg/dL (Table 5).</paragraph>
                        <table ID="ID58" width="0" styleCode="Noautorules">
                           <caption>  Table 5: Mean Serum Phosphorus (mg/dL) at Baseline and Endpoint </caption>
                           <col width="340"/>
                           <col width="152"/>
                           <col width="125"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Sevelamer Hydrochloride Tablets</content>
                                    <br/>
                                    <content styleCode="bold"> (N=81)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Active-Control</content>
                                    <br/>
                                    <content styleCode="bold"> (N=83)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Baseline at End of Washout<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Endpoint<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Change from Baseline at Endpoint<br/> (95% Confidence Interval)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> -2.0*<br/> (-2.5, -1.5)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> -2.1*<br/> (-2.6, -1.7)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="left"> *p&lt;0.0001, within treatment group comparison<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID59">The distribution of responses is shown in Figure 2. The distributions are similar for sevelamer hydrochloride and active control. The median response is a reduction of about 2 mg/dL in both groups. About 50% of subjects have reductions between 1 and 3 mg/dL.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2: Percentage of Patients (Y-axis) Attaining a Phosphorus Reduction from Baseline (mg/dL) at Least as Great as the Value of the X-axis </content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph ID="ID61">Average daily sevelamer hydrochloride dose at the end of treatment was 4.9 g (range of 0.0 to 12.6 g).</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID62">
                     <id root="51cb40d6-7c91-4f06-8f8c-5e23d818c5f9"/>
                     <title>14.2 Active-Control, Parallel Study in Hemodialysis Patients</title>
                     <text>
                        <paragraph ID="ID63">Two hundred CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus &gt;5.5 mg/dL) following a two-week phosphate-binder washout period were randomized to receive sevelamer hydrochloride 800 mg tablets (N=99) or an active control (N=101). The two treatments produced similar decreases in serum phosphorus. At week 52, using last observation carried forward, sevelamer hydrochloride and active control both significantly decreased mean serum phosphorus (Table 6).</paragraph>
                        <table ID="ID64" width="591" styleCode="Noautorules">
                           <caption>  Table 6: Mean Serum Phosphorus (mg/dL) and Ion Product at Baseline and Change from Baseline to End of Treatment </caption>
                           <col width="197"/>
                           <col width="197"/>
                           <col width="197"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Sevelamer Hydrochloride Tablets</content>
                                    <br/>
                                    <content styleCode="bold"> (N=94)</content>
                                    <br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Active-Control</content>
                                    <br/>
                                    <content styleCode="bold"> (N=98)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Phosphorus<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Rrule"/>
                                 <td valign="bottom" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Baseline<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Rrule" align="center"> 7.5<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Rrule" align="center"> 7.3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Change from Baseline at Endpoint<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> -2.1<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> -1.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Ca x Phosphorous Ion Product<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Rrule"/>
                                 <td valign="bottom" styleCode=" Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Rrule" align="left"> Baseline<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Rrule" align="center"> 70.5<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Rrule" align="center"> 68.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Change from Baseline at Endpoint<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> -19.4<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> -14.2<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID65">Sixty-one percent of sevelamer hydrochloride patients and 73% of the control patients completed the full 52 weeks of treatment.</paragraph>
                        <paragraph>Figure 3, a plot of the phosphorus change from baseline for the completers, illustrates the durability of response for patients who are able to remain on treatment.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Mean Phosphorus Change from Baseline for Patients who Completed 52 Weeks of Treatment</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph ID="ID67">Average daily sevelamer hydrochloride dose at the end of treatment was 6.5 g (range of 0.8 to 13 g).</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <section ID="ID68">
                     <id root="3bea1da2-23c4-4c76-886e-70d21faade22"/>
                     <title>14.3 Active-Control, Parallel Study in Peritoneal Dialysis Patients</title>
                     <text>
                        <paragraph ID="ID69">One hundred and forty-three patients on peritoneal dialysis, who were hyperphosphatemic (serum phosphorus &gt;5.5 mg/dL) following a two-week phosphate-binder washout period, were randomized to receive sevelamer hydrochloride (N=97) or active control (N=46) open label for 12 weeks. Average daily sevelamer hydrochloride dose at the end of treatment was 5.9 g (range 0.8 to 14.3 g). There were statistically significant changes in serum phosphorus (p&lt;0.001) for sevelamer hydrochloride (-1.6 mg/dL from baseline of 7.5 mg/dL), similar to the active control.</paragraph>
                     </text>
                     <effectiveTime value="20250205"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f9b9e637-d236-4bc0-afca-bbbf1b1747ab-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f9b9e637-d236-4bc0-afca-bbbf1b1747ab-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID70">
               <id root="5a0d9cab-4118-40a3-a7a7-1efa5523d3f7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID71">Sevelamer hydrochloride tablets are supplied as white to off-white, oval shaped film-coated tablets, debossed with "NAV" on one side and debossed with "110" on other side.</paragraph>
                  <paragraph>Sevelamer hydrochloride tablets 800 mg are packaged in bottles of 180 tablets.</paragraph>
                  <paragraph>1 Bottle of 180 counts 800 mg Tablets (NDC 70710-2058-8)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).</paragraph>
                  <paragraph>Do not use sevelamer hydrochloride tablets after the expiration date on the bottle.</paragraph>
                  <paragraph>[See USP controlled room temperature]</paragraph>
                  <paragraph>Protect from moisture.</paragraph>
               </text>
               <effectiveTime value="20250205"/>
            </section>
         </component>
         <component>
            <section ID="ID100">
               <id root="ca1bed82-55bf-4d94-9b06-9d524a629def"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID101">Advise patients to take sevelamer hydrochloride tablets with meals and adhere to their prescribed diets.</paragraph>
                  <paragraph>Provide instructions on concomitant medications that should be dosed apart from sevelamer hydrochloride tablets.</paragraph>
                  <paragraph>Advise patients to report new onset or worsening of existing constipation or bloody stools promptly to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID15">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>Zydus Pharmaceuticals (USA) Inc.</paragraph>
                  <paragraph>Pennington, NJ 08534</paragraph>
                  <paragraph>31101224 R2</paragraph>
               </text>
               <effectiveTime value="20250205"/>
            </section>
         </component>
         <component>
            <section ID="ID90">
               <id root="d9a99e47-4423-4a96-acef-a157235849f6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250205"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>pdp-bottle</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f9b9e637-d236-4bc0-afca-bbbf1b1747ab-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>